Prof. Dr. Rienk Offringa started off as a molecular biologist, studying gene regulation in cancer, but when he witnessed the power of T-cell therapy in pre-clinical mouse models, he decided to focus his post-doctoral career on cancer immunotherapy. After a post doc at Dana Farber Cancer Institute in Boston, Dr. Offringa went back to his ‘alma mater’ in Leiden, The Netherlands, to head the Tumor Immunology Laboratory at Leiden University Medical Center. Subsequently, he worked at Genentech Inc. in San Francisco, where he focused on the development of immunotherapeutic drugs. After 4 years in Industry (in 2011), Dr. Offringa moved back to academia and back to Europe, by accepting a full professorship at University Hospital Heidelberg and DKFZ. He is currently running two labs, one focusing on pancreatic cancer and cancer immunotherapy, and a second dedicated to the development of cancer immunotherapy drugs, co-funded by DKFZ and Bayer Healthcare.